Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C8H13N5O4.ClH |
Molecular Weight | 279.681 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NC(=N)C1=NN(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O
InChI
InChIKey=PIGYMBULXKLTCJ-UHSSARMYSA-N
InChI=1S/C8H13N5O4.ClH/c9-6(10)7-11-2-13(12-7)8-5(16)4(15)3(1-14)17-8;/h2-5,8,14-16H,1H2,(H3,9,10);1H/t3-,4-,5-,8-;/m1./s1
Taribavirin, an oral prodrug of ribavirin that was developed as nucleoside antimetabolite, which interferes with duplication of viral genetic material. Taribavirin was studied in phase III clinical trial for the treatment of chronic hepatitis C patients. However, this drug not yet approved for pharmaceutical use.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Synthesis and antiviral activity of 1,2,4-triazole-3-thiocarboxamide and 1,2,4-triazole-3-carboxamidine ribonucleosides. | 1973 Aug |
|
Effects of ribamidine, a 3-carboxamidine derivative of ribavirin, on experimentally induced Phlebovirus infections. | 1988 Dec 1 |
|
Treatment of lethal Pichinde virus infections in weanling LVG/Lak hamsters with ribavirin, ribamidine, selenazofurin, and ampligen. | 1993 Jan |
|
Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections. | 1994 Oct |
|
Identification of active antiviral compounds against a New York isolate of West Nile virus. | 2002 Jul |
|
Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin. | 2004 Oct |
|
New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents. | 2010 |
|
Hepatitis C and kidney disease. | 2010 |
|
Antiviral therapy for hepatitis C virus: beyond the standard of care. | 2010 Apr |
|
The next step for taribavirin. | 2010 Oct |
|
Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. | 2010 Oct |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00230958
viramidine (TARIBAVIRIN) 600 mg BID
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C281
Created by
admin on Fri Dec 15 15:56:54 GMT 2023 , Edited by admin on Fri Dec 15 15:56:54 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID50960781
Created by
admin on Fri Dec 15 15:56:54 GMT 2023 , Edited by admin on Fri Dec 15 15:56:54 GMT 2023
|
PRIMARY | |||
|
300000045471
Created by
admin on Fri Dec 15 15:56:54 GMT 2023 , Edited by admin on Fri Dec 15 15:56:54 GMT 2023
|
PRIMARY | |||
|
C77929
Created by
admin on Fri Dec 15 15:56:54 GMT 2023 , Edited by admin on Fri Dec 15 15:56:54 GMT 2023
|
PRIMARY | |||
|
DBSALT002011
Created by
admin on Fri Dec 15 15:56:54 GMT 2023 , Edited by admin on Fri Dec 15 15:56:54 GMT 2023
|
PRIMARY | |||
|
40372-00-7
Created by
admin on Fri Dec 15 15:56:54 GMT 2023 , Edited by admin on Fri Dec 15 15:56:54 GMT 2023
|
PRIMARY | |||
|
SUB21031
Created by
admin on Fri Dec 15 15:56:54 GMT 2023 , Edited by admin on Fri Dec 15 15:56:54 GMT 2023
|
PRIMARY | |||
|
m10467
Created by
admin on Fri Dec 15 15:56:54 GMT 2023 , Edited by admin on Fri Dec 15 15:56:54 GMT 2023
|
PRIMARY | Merck Index | ||
|
451447
Created by
admin on Fri Dec 15 15:56:54 GMT 2023 , Edited by admin on Fri Dec 15 15:56:54 GMT 2023
|
PRIMARY | |||
|
D22JZE246P
Created by
admin on Fri Dec 15 15:56:54 GMT 2023 , Edited by admin on Fri Dec 15 15:56:54 GMT 2023
|
PRIMARY | |||
|
CHEMBL2111108
Created by
admin on Fri Dec 15 15:56:54 GMT 2023 , Edited by admin on Fri Dec 15 15:56:54 GMT 2023
|
PRIMARY | |||
|
QQ-41
Created by
admin on Fri Dec 15 15:56:54 GMT 2023 , Edited by admin on Fri Dec 15 15:56:54 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD